#United States #New York #Gross Law #Geron Corporation #imetelstat

Important Notice for Geron Corporation Shareholders

In a recent announcement from The Gross Law Firm, shareholders of Geron Corporation (NASDAQ: GERN) are strongly encouraged to reach out before May 12, 2025, to discuss their rights regarding potential recoveries linked to their investments. This notice aims to make those who purchased shares during a specified class period aware of their legal options.

Background on Geron Corporation

Geron Corporation focuses on developing innovative therapies for cancer, particularly with their notable drug Rytelo (imetelstat). However, recent developments have raised concerns about the company's growth potential in the market. Investors who bought shares from February 28, 2024, to February 25, 2025, are particularly highlighted as they might have significant claims resulting from misleading information disclosed by the company.

Issues Raised in the Allegations

According to the complaint, Geron's executives allegedly misled investors regarding the company's expectations for Rytelo, presenting overly optimistic projections about its market viability. They portrayed confidence in capturing the unmet medical needs for patients who did not qualify for first-line therapies by minimizing critical risks, such as the necessity for frequent monitoring and the competitive landscape affecting the product's sales growth.

On February 26, 2025, Geron revealed disappointing financial results for the last quarter of 2024, indicating that Rytelo's growth had stagnated due to several factors, including competition, consumer awareness challenges, and the burdensome monitoring requirements for its administration. This revelation drove the stock price from $2.37 on the preceding day to $1.61, reflecting a staggering decline of about 32.07% in just one day, a significant red flag for investors.

Next Steps for Shareholders

Geron shareholders who acquired their shares during the designated class period should not hesitate to register for this class action lawsuit to secure their potential recovery options. By registering, investors will be provided with updates and insights throughout the litigation process via a dedicated portfolio monitoring platform.

It is essential to complete your registration before the deadline of May 12, 2025. Participation does not incur costs, and acting swiftly could mean the difference in recovering potential losses.

Why Choose The Gross Law Firm?

The Gross Law Firm is recognized as a national leader in class action lawsuits, committed to protecting the rights of investors suffering losses due to deceptive corporate conduct. Their mission emphasizes accountability in corporate behavior, ensuring companies adhere to ethical business practices that inform investors transparently.

If you've been impacted by the recent downturn of Geron's stock due to misleading statements or the omission of critical information, do not miss this opportunity to assert your rights. Early action could lead to potential financial recovery.

Contact Information

To initiate this process or for further inquiries, please reach out directly via the contact details provided below:

• - Address: The Gross Law Firm, 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: contact@grosslawfirm.com
• - Phone: (646) 453-8903

Ensure that your voice is heard and that your investment rights are safeguarded—act before the deadline on May 12, 2025.